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Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is aﬀected
by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well
as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous
multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies
in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum
lipidsandepidermalphospholipids,serumlipids,dermallow-densitylipoproteinsinthepsoriaticskin,lipidmetabolism,oxidative
stress and correlations between inﬂammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of
the literature data, psoriasis can be described as an immunometabolic disease.
1.Introduction
Psoriasis is a common disease aﬀecting, as presumed, ap-
proximately 120–180 million people worldwide [1]. Around
150,000 new cases of psoriasis are reported annually. There
are fewer reports on the incidence of psoriasis, but in recent
studies an increasing trend over the last 3 decades was
shown [1, 2]. The population prevalence of psoriasis has
been reported to range from 2% to 3%. However, in some
countries there is a higher prevalence rate for psoriasis,
for example in Kazakhstan, Trinidad and Tobago, Paraguay,
Kenya, Tanzania, Egypt, and Kuwait [3]. Four hundred
people die annually from psoriasis-related causes in the
Unites States [1]. Psoriasis prevalence in the population is af-
fected by genetic, environmental, viral, infectious, immuno-
logical, biochemical, endocrinological, and psychological
(trauma, stress) factors as well as alcohol and drug abuse
[4, 5].
In the recent years, psoriasis has been recognised as
a systemic disease associated with numerous multiorgan
abnormalities and complications. In psoriatic patients an
increased risk of cardiovascular abnormalities, hypertension,
dyslipidemia, atherosclerosis, diabetes mellitus type 2, obe-
sity, chronic obturative pulmonary disease, cerebral stroke,
osteoporosis, cancer, and depression was noticed [6–8].
Lipid metabolism research studies in psoriasis have been
started at the beginning of the 20th century from the quan-
titative analysis of serum cholesterol in psoriatic patients
[9]. The abnormal fat metabolism was considered to be an
important factor in the etiopathogenesis of psoriasis. Gr¨ utz
and Burger examined the development of psoriatic skin
manifestations as a symptom comparable to xanthomatosis
[9, 10]. Melczer found changes in the composition of
phospholipids in psoriatic foci and suggested that inﬂam-
mation, congestion, and parakeratosis resulted from lipid
deposition in the reticular-endothelial system [11]. It was
also suggested that continuous separation of psoriatic scales
causedthepermanentlossoflipidswhichmightaﬀectserum
lipid abnormalities [11, 12]. Lipid metabolism is a complex
process which takes place in diﬀerent human organs and
peripheralblood(Figure 1)[13].Itsdisturbances inpsoriasis
need further studies to be fully elucidated. There are some2 Mediators of Inﬂammation
new methods for diagnosis of cholesterol in the healthy skin
available; however its exact usefulness should be carefully
recognised [14, 15].
Nowadays the studies are concentrated on the skin sur-
face lipids, epidermal lipids (including stratum corneum
lipids, and epidermal phospholipids), serum lipids, der-
mal low-density lipoproteins in the psoriatic skin, lipid
metabolism, oxidative stress and correlations between in-
ﬂammatory parameters, lipid parameters, and clinical symp-
tomsofthedisease(Figure 2)[10–12,16–19].Theaimofthis
study is to present an update of the lipid studies in psoriasis
on the basis of the literature review.
2. Skin Surfaceand EpidermalLipids
The stratum corneum consists of corneocytes and intra-
cellular lipids, mainly ceramides, sterols, and free fatty
acids which form the barrier for diﬀusion of substances
into the skin [20–23]. The lipids are organised into
multilamellar intercellular membranes derived from glyc-
erophospholipids, glucocerebrosides, sphingomyelin of the
stratum granulosum-stratum corneum interface [23, 24].
Then the precursors are converted to ceramides and free
fatty acids by the hydrolytic enzymes [25, 26]. In psoriasis,
alterations in ceramide content have been demonstrated [27]
and abnormal lipid structures reported [28]. Total lipids,
phospholipids, triacylglycerols, and cholesterol were found
to increase both in blood and in epidermis of psoriatic
patients [29, 30]. The proportion of an esteriﬁed fraction
decreased mainly in the normally appearing epidermis
areas, especially in severe psoriasis [31]. In the gas liquid
chromatography,signiﬁcantlylowerspectrumofshort-chain
fatty acids (SCFAs) levels were detected in both psoriatic and
uninvolved areas [32]. The correlation was found between
increased levels of free and total cholesterol as well as
phospholipids in the epidermis and the severity of psoriasis
[31, 32].
The main features of the corneous layer observed under
the scanning electron microscope include widened intracel-
lularspaces,lackofresistantintercellularjunctions,impaired
intracellular adhesion, which may result in markedly abnor-
mal cholesterol homeostasis [33, 34]. In the lipid thin-layer
chromatography,anincreasedamountoftotalphospholipids
was found in the involved psoriatic epidermis whereas
the decrease of phosphatidylserine and the increase of
phosphatidylinositol were observed in psoriatic lesions and
in the lesion-free epidermis [35].
Lacroix demonstrated signiﬁcant amount of cholesterol
in scaly plagues and in serum. He suggested that psoriasis
might be the form of cholesterol elimination through the
skin [9]. The regulation of cellular cholesterol metabolism is
already fully developed in the foetal life. The maintenance of
its steady cellular levels is an important element of cellular
and systemic homeostasis. It is already known that this
homeostasis is disturbed in psoriasis [10]. Every day about
85mg of cholesterol is secreted through the healthy skin. In
psoriasis,thepatientslostdaily12–23.5-foldmorelipidswith
the scales than healthy subjects [18, 36, 37].
3.SerumLipids
Serum lipids levels were examined in many diﬀerent groups
of psoriatic patients in comparison to relevant healthy
controls [9–11, 16, 18, 38–48]. The blood lipid results are
considerably dependent on group matching (age, gender,
and ethnic and cultural factors). In most of the studies,
a statistically signiﬁcant elevated level of total cholesterol
(TC), low-density lipoprotein (LDL) cholesterol and/or
triglycerides (TG) in psoriatic patients was demonstrated
comparing to a healthy control group [11, 16, 18, 39, 40, 43–
47, 49–52]. Moreover, there was a decrease of high density
lipoprotein (HDL) cholesterol in the serum of psoriatic
patients [43, 48, 50–53]. Only in a few studies no diﬀerences
in lipid serum levels between psoriatic patients and healthy
controls were observed [38, 42, 54].
Nowadays there is an increased interest in HDL choles-
terol, because clinical and epidemiological studies showed
an inverse relationship between the level of HDL and the
developmentofatherosclerosis[55].HDLisaveryimportant
factor in reverse cholesterol transport (RCT). It takes part in
the transport of cholesterol produced or accumulated in the
peripheral tissues to the liver or other steroidogenic tissues
and exerts the antioxidant, anti-inﬂammatory, antithrom-
botic and ﬁbrinolytic action [55]. It should be underlined
that neither HDL nor LDL is “bad cholesterol,” because
both are essential for the proper transport of cholesterol
(Figure 3).
Resultsofthestudiespresentadecreaseofcholesteroland
phospholipids levels connected with HDL fraction indepen-
dently of psoriasis severity and duration [36]. In psoriasis,
a decrease of HDL synthesis and HDL structural changes
can be observed, due to various biochemical disturbances,
such as abnormalities of receptor function, changes of hep-
atic structure and function, activity changes of hepatocyte
membranes, impaired RCT, esteriﬁcation, and lipases [36]. It
can be hypothesised that HDL structural changes are caused
by a decrease of cholesterol and phospholipids level as well
as an increase of apolipoprotein A (apoA) concentration
in the HDL coat. So far, all the studies were based on
the quantitative evaluation of lipids in the psoriatic patient
serum and epidermis. Further studies are needed to specify
the role of disturbances of HDL structure and composition
as well as connections between lipid abnormalities and the
immune response in psoriasis.
Thestudiesconcerningtheconcentrationofserumphos-
pholipids in the psoriatic patients present diﬀerent results. A
decrease of concentration of total phospholipids, as well as
phosphatidylethanolamine, lecithin, the lecithin:cholesterol
ratio and linolenic acid, docosatetraenoic acid, docosapen-
taenoic acid, and docosahexaenoic acid in the serum was
observed [57–61]. There was also an increased level of some
fractions of serum phospholipids (e.g., lysolecithin) and
palmitic acid, palmitoleic acid, and dihomo-γ-linolenic acid
(DHLA) [57, 58, 62–64]. Some reports, however, do not
present any diﬀerences in the level of serum phospholipids
between psoriatic patients and healthy control group [65].
Our results did not show any statistically signiﬁcant diﬀer-
ences in the level of total phospholipids, but the decreasingMediators of Inﬂammation 3
Billary
cholesterol
≈ 75%
Dietary
cholesterol
≈ 25%
Bile acids
Micellar
cholesterol
Intestines
Liver
Systemic
Cholesterol
LDL-C, CM, TG, HDL-C
JNK
Akt Hepatic ApoB 100
VLDL
Intestitial ApoB 48
Peripheral
cholesterol
LDL receptors
Skin
Figure 1: Cholesterol traﬃcking in human organism. CM: chylomicrones, HDL-C: high-density lipoproteins cholesterol, LDL-C: low-
density lipoproteins cholesterol, VLDL-C: very low-density lipoproteins cholesterol, TG: triglycerides, JNK: Janus-family tyrosine kinase,
and Akt: kinase Akt. The ﬁgure is adapted after permission from [13]. The complete electronic version of this article can be found online at:
http://www.lipidworld.com/content/8/1/41.
tendency of its level was seen in both normolipidemic and
hyperlipidemic patients [10].
4.Apolipoproteins
Apolipoproteins are the protein part of lipoproteins, and
their composition is speciﬁc for each lipoprotein. They have
ad i ﬀerent molecular structure, amino acid composition,
and antiatherosclerotic properties. In psoriatic patients,
diﬀerent results concerning apolipoproteins apoA1, apoB,
and apoE were presented [16, 41, 66, 67]. Apolipoprotein
A1 has been immunocytochemically detected at the psoriatic
skin dermoepidermal junction, vascular walls, and the
perivascularregionofpapillarydermis.ApolipoproteinB100
and apolipoprotein E were observed intracellularly both in
normal epidermis and psoriatic epidermis, and they were
also detected in parakeratotic regions in the horny layer [68].
ApoA1 plays the main part in the reverse cholesterol
transport from the peripheral cells to the liver. Its decreased
level has an inﬂuence on the higher risk of atherosclerosis
development [69]. ApoA2 stabilizes the HDL structure and
is considered as the lecithin:cholesterol acetyltransferase
(LCAT) inhibitor. Its role concerning atherosclerosis is
controversial, because it was shown that apoA1 impaired
the inﬂow of cholesterol from adipocytes to the extracellular
space [70]. Elevated levels of apolipoproteins A1 and A2
accompanytheintakeofalcohol.ThelevelofapoA1increases
also in familiar hyperproteinemia, in pregnancy, during
estrogen therapy, and during physical exercise.
Elevated levels of apolipoprotein B are associated with
the increased risk of atherosclerosis, due to its role in the
cholesterol accumulation in the endothelium, which initiates
the atheromatous process. Apo B elevated levels are observed
in the hyperlipidemia type IIa, IIb, IV, and V, in nephritic
syndrome, pregnancy, familiar hyperapo-ß-lipoproteinemia,
biliary obstruction, smokers, and dialyzed patients on treat-
ment with diuretics ß-blockers, cyclosporine, or glucocorti-
coids [71].
Apolipoprotein C3 (apoC3) is suggested to inhibit
lipoprotein lipase [72, 73] and hepatic triglyceride lipase
[74], enzymes responsible for the clearance of triglyceride
rich particles from the plasma. Furthermore, apoC3 was
shown to inhibit the hepatic uptake of triglyceride rich
particles [75]. Apo C3 also appears to interfere with HDL
receptor-mediated uptake of lipoproteins. It is known that
an increase in apoC3 levels induces the development of
hypertriglyceridemia.
In most studies, elevated levels of apoA1, apoB [16, 43],
apoC3, and apoE [41, 76–78] were detected in the serum
of psoriatic patients compared to the healthy control group.
However, there are also contrary results showing decreased
levels of apolipoproteins [79]. Many authors did not show
any diﬀerences in apoA1, apoA2, and apoB levels between
psoriatic patients and the control group [10, 76, 80]. It
was also reported that apoA1 sequestration in the inﬂamed
tissues might lead to reduced HDL-C serum levels and
thus increase the risk of cardiovascular disease in psoriatic
patients [81].
Apolipoprotein E (ApoE) is a glycoprotein involved in
the regulation of triglycerides and low-density lipoprotein
(LDL) levels [67]. ApoE can modulate mitogen-activated T-
lymphocyte proliferation in vitro and provides protection
against some infections [82, 83] .T h er o l eo ft h ea p o E
gene in psoriasis was suggested, because in psoriatic skin
there is the downregulation of ApoE expression and the
normalization of ApoE levels precedes clinical improvement
[67]. Furthermore, in a Japanese population the epsilon
2 allele was found to be signiﬁcantly more frequent in4 Mediators of Inﬂammation
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Figure 2: Inﬂuence of the psoriasis associated dyslipidemia on human organs. This ﬁgure is based (after permission) on the ﬁgure from
[19].
psoriatic patients than in controls, suggesting that there
may be a relationship between these particular alleles and
development of psoriasis [84]. It is believed that the epsilon
4 allele could be a risk factor for developing a severe form of
psoriasis [85].
5. OxidativeStress
Reactive oxygen species (ROSs) such as hydroxyl rad-
ical (HO￿) ,p e r o x y lr a d i c a l s( R O O ￿), superoxide anion
(O2
￿−),hydrogen peroxide (H2O2), nitrogen oxide (NO￿),
and hypochlorous acid (HOCl) are constantly produced
as a result of metabolic reactions in living systems [86].
Oxidative stress may be deﬁned as an imbalance between
cellular production of ROS and antioxidant defence mech-
anisms. It leads to oxidative damage of lipids and proteins
contributing to barrier integrity, which is essential for
healthy skin conditions [18, 87, 88]. The skin antioxidant
system consists of a network of both enzymatic (glutathione
peroxidase (GSH-Px), catalase (CAT), superoxide dismu-
tase (SOD), and paraoxonase (PON1)) and nonenzymaticMediators of Inﬂammation 5
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antioxidants. Nonenzymatic antioxidants (glutathione, β-
carotene, ascorbic acid, and tocopherols) present in cells are
regarded as protectors against the lipid peroxidation [88].
Increasedproductionofoxygenmetabolites,overwhelm-
ing the antioxidant capacity of the body, is an important
feature in psoriasis [87]. Early and active psoriatic lesions
are characterized by the intraepidermal penetration of
activated polymorphonuclear leucocytes which leads to ROS
production provided by NADPH oxidase and proteolytic
enzymes [88]. The production of ROS can be indirectly
assessed by the levels of lipid peroxidation products such as
lipid hydroperoxide (LHP), malondialdehyde (MDA), oxi-
dized low-density lipoprotein (ox-LDL), and thiobarbituric
acid (TBA) [87]. Patients with psoriasis exhibit increased
concentrations of MDA [51, 87, 89, 90] and ox-LDL [18]i n
the tissues and higher levels of TBA [43, 52, 87]a n da n t i - o x -
LDL autoantibody (AuAb-oxLDL) [50, 51, 87] in the blood.
The lipid peroxidation markers were found signiﬁcantly
higher in the patients with severe or active psoriasis (PASI
> 3) than in the patients with mild or inactive psoriasis
(PASI < 3) [43]. The accumulation of ox-LDL was detected
in the upper epidermis of the involved skin from psoriatic
patients by direct immune-ﬂuorescent method [18]. Ox-
LDLs are able to initiate inﬂammation and to inﬂuence the
adhesion of endothelial cells and on oxidant status of the
blood vessels cells, which is important in the development of
earlyatherogenesis[53].Theyarealsoantigenicandcanelicit
an immune response with a generation of circulating anti-
bodies AuAb-oxLDL and β2-GP1-dependent anticardiolipin
antibodies (aCL), as a consequence of structural similarity
between ox-LDL surface structure and β2-GP1-anionic
phospholipid complex, the antigenic target for aCL [91].
The level of AuAb-oxLDL has been suggested to reﬂect the in
vivo oxidation of LDL. The importance of AuAb-oxLDL in
diseases such as myocardial infarct, atherosclerosis, diabetes
mellitus, renal failure, systemic lupus erythematosus (SLE),
rheumatoidarthritis(RA),Behσet’sdisease,andpsoriasiswas
suggested [51]. aCL level is increased in psoriatic patients.
It could be a useful marker in predicting atherosclerosis
risk, because it may promote atherosclerotic lesions [91].
In plasma and red blood cells (RBCs) of psoriatic patients,
increased levels of MDA were observed which indicates an
advanced peroxidative process in erythrocyte membranes.
The increased peroxidation of lipid bilayer caused by a
decreaseofantioxidantenzymeactivitiesmaybetheessential
mechanism of the membrane ﬂuidity decrease observed in
association with the exacerbation of the disease [88, 89, 92].
Theimpairedantioxidantstatusisshownbydecreasedserum
levels of erythrocyte SOD [51, 90] and GSH-Px activities
[51, 90, 92, 93] of increased PON1 activity [54]a n do f
increased [90] or decreased [51] serum CAT activity in
patients with psoriasis. Nonenzymatic antioxidants were also
decreased [51, 92, 93]. Changes in the elastase neutrophil
ratio illustrating an increase in neutrophil function can be
a marker of psoriasis [43]. In general, total antioxidant
status (TAS) in psoriasis is reduced [43, 51], or there are no
signiﬁcant diﬀerences between patients and healthy controls
[52, 54, 89].
A high serum total homocysteine (tHcy) level was
observed in patients with psoriasis. The main mechanisms
of hyperhomocysteinemia engaged in the development of
atherothrombosis are endothelial injury, platelet activa-
tion, oxidative modiﬁcation of low-density lipoproteins,
and endothelial-leukocyte interactions [94, 95]. There was6 Mediators of Inﬂammation
a positive relationship between an increased level of AuAb-
oxLDL and plasma tHcy levels which may play an important
role in development of atherothrombotic complications in
psoriatic patients [96].
Oxidativestressmayhaveapivotalroleinboththerapeu-
tic mechanisms and side eﬀects induced by anthralin. Sys-
temic antioxidant administration may provide an opportu-
nityfortherapeuticinterventionagainstanthralin-associated
toxicities [88]. Lipid peroxidation is the earliest response
mediating activation of downstream signalling events in
peripheral blood mononuclear cells (PBMCs) and ker-
atinocytes by anthralin. It leads to the activation of c-jun-
N-terminal kinase (JNK), event relevant for the regulation of
cellular proliferation and apoptosis [97].
It is well known that phototherapy is recommended in
the psoriasis treatment. However, both ultraviolet A and
B radiation (UVA and UVB) apart from therapeutic and
immunomodulating action induce production of ROS and
increase lipid peroxidation [53]. There was a diﬀerence
between the eﬀect of phototherapy on lipid parameters in
patients with mild or moderate psoriasis (PASI1 from 5.4 to
22.1; mean 15.2±4.9) and severe psoriasis (PASI 2, PASI 22.5
to 49.2; mean 30.3 ± 5.8). Exacerbated skin manifestations
of psoriasis are accompanied by an increase of dyslipidaemia
and oxidation processes. Therefore patients with severe
psoriasis are exposed to higher risk of atherosclerosis. PASI2
patients have higher level of AuAb-oxLDL than PASI1
patients.PhototherapyincreasedTC,LDL,andAuAb-oxLDL
level in PASI1 patients. Level of ox-LDL was decreased
after phototherapy in patients with severe psoriasis and
it was accompanied by increase of ferric reducing ability
of plasma (FRAP) and negative correlation with AuAb-
oxLDL level. It can be explained by therapeutic action
of phototherapy and reduction of inﬂammatory processes
[53].
6. Peroxisome Proliferator-Activated Receptors
(PPARs) andLiverXReceptors(LXRs)
Theepidermisisaveryactivesiteoflipidmetabolism,andall
peroxisome proliferator-activated receptor (PPAR) and liver
Xreceptor(LXR)isoformsareexpressedintheepidermis.An
increased expression of PPARβ/δ and a decreased expression
of PPARα and PPARγ were observed in the lesional skin
of patients with psoriasis and atopic dermatitis [98–100].
Since the prevalence of metabolic syndrome is increased in
psoriasis [101], a combination of insulin resistance, obesity,
or chronic inﬂammation may trigger the expression of
PPARβ/δ, which in turn contributes to a nonterminated
regenerative skin phenotype. This disease mechanism would
beexpectedtobeaggravatedbyacuteinﬂammation,orstress
via the induction of PPARβ/δ by TNFα and stress-activated
kinase [102].
PPARs α, β/δ, γ,a n dL X R sα and β belong to the nuclear
steroid hormone receptor superfamily, which are regulated
by fatty acid derivatives capable of controlling lipid and
lipoprotein metabolism, cell proliferation, diﬀerentiation,
and apoptosis of various cell types, including keratinocytes
and sebaceous gland cells. These receptors play also a role in
cutaneous carcinogenesis [100].
An activation of PPARs and LXRs leads to stimulation
of epidermal lipid synthesis, formation and secretion of
lamellar bodies, and activation of enzymes required for the
extracellular processing of lipids in the stratum corneum,
resulting in the formation of lamellar membranes that
mediate permeability barrier function. PPARγ activation
appeared to have the least eﬀect on epidermal lipid synthesis
among the PPAR and LXR activators tested. PPARβ/δ is the
key PPAR isoform involved in lamellar body formation and
secretion as well as in lipid storage [103, 104].
PPAR-α can also modulate the inﬂammatory response
by inhibiting cytokine secretion, maturation, and migration
and the T-cell-stimulatory activity of the epidermal antigen-
presenting cell, the Langerhans cell. This was associated with
decreased levels of phosphorylated nuclear factor-κB( N F -
κB) [105]. Moreover, PPAR-α activation induces antioxidant
enzymes, such as catalase or SOD, which would reduce the
oxidative stress and the activation of mediators of inﬂamma-
tory response [88]. The anti-inﬂammatory role of PPARβ/δ
and PPARγ in the skin is uncertain, but it is suggested
that they downregulate inﬂammation. LXR activators have
a potent anti-inﬂammatory activity in both the irritant
and allergic contact models of cutaneous inﬂammation
[106, 107]. These ﬁndings suggest the possibility of PPAR-α
activators as novel nonsteroidal anti-inﬂammatory drugs in
thetopicaltreatmentofcommoninﬂammatorydiseasessuch
as atopic dermatitis, psoriasis, acne, and photodermatitis.
A great improvement of skin lesions and also of psoriatic
arthritis had been initially documented in patients with
psoriasis treated with the oral PPARγ activators troglitazone
[108, 109] or pioglitazone [110–112]. In contrast, topical
treatment of psoriatic skin with the PPAR activators tetrade-
cylthioaceticacidandrosiglitazonedidnotshowasigniﬁcant
eﬀect [113, 114].
LXR and PPAR inﬂuence also the synthesis of cholesterol
sulfate, which is a potent regulator of epidermal diﬀer-
entiation and corneocyte desquamation. The stimulation
of both the cellular and extracellular components of the
stratum corneum by PPARα and LXR activators results
in the generation of a mature, functionally competent
stratum corneum earlier in fetal development. Moreover, in
a mouse model of epidermal hyperproliferation induced by
repeated barrier disruption to the ﬂank skin of hairless mice
[115], topical PPARα activation inhibited proliferation and
increased keratinocyte apoptosis. The activation of PPARα
in the epidermis decreases keratinocyte proliferation. The
absence of PPARβ/δ leads to increased keratinocyte prolif-
eration and under some experimental conditions PPARβ/δ
activators inhibit keratinocyte proliferation. It has been
demonstrated that activation of PPARβ/δ induces endothe-
lialcellproliferationandangiogenesis[116].Itwassuggested
that in the hyperproliferative epidermis of psoriatic skin,
PPARβ/δ overexpression mediates keratinocyte proliferation
via NF-κB[ 98]. The proliferative state of the keratino-
cytes may determine the eﬀect of PPARγ activation on
keratinocyte proliferation. A proapoptotic eﬀect of PPARγ
in T cells has been observed [117], and activation ofMediators of Inﬂammation 7
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Figure 4: Psoriasis and cardiovascular abnormalities. This ﬁgure is a modiﬁed one (after permission) from [19].
PPARγ has an inhibitory eﬀect on psoriasis, whereas this
is not the case with PPARβ/δ activation [118, 119]. In
LXRs deﬁcient mice, thinning of the epidermis was observed
[120].
7.CardiovascularDisease(CVD)
In patients with psoriasis one observes an increased risk
of cardiovascular disease which can be explained by several
possible biological factors [6, 121–125]. Psoriasis is associ-
ated with traditional risk factors of CVD such as increased
BMI, hyperlipidemia, hypertension, type 2 diabetes mellitus,
and cigarette smoking [124–126]. Obesity has been shown
to be an independent risk factor for the development of
psoriasis and is also associated with more severe psoriasis
and cardiovascular complications [125]. The persistent skin
inﬂammation may contribute to a dyslipidemia and pre-
mature atherosclerosis [126, 127]. The duration of disease
and its severity are related to the incidence of cardiovascular
diseases, such as myocardial infarction, coronary artery
disease and stroke [16, 38–40, 43–47, 54, 101, 121, 122, 127–
135]. In psoriatic patients, lipid abnormalities are correlated
with increased mortality due to myocardial infarction and
stroke [129, 134]. Elevated level of C-reactive protein (CRP)
is a risk factor for CVD and it can predict long-term risk
for cardiovascular events [136]. The treatment for psoriasis
such as retinoids and cyclosporine may be also respon-
sible for initiation of hyperlipidemia which can promote
future CVD [137–141]. Methotrexate use is associated with
hyperhomocysteinemia, also a risk factor for cardiovascular
disease [142].
There was a strong association observed between arterial
stiﬀness, which is endothelial dysfunction marker, and the
risk of cardiovascular events. Pulse wave velocity (PWV) is
the gold standard measurement of arterial stiﬀness and in
thepatientswithpsoriasisandpsoriaticarthritisanincreased
femoral-carotid PWV was observed [127, 143]. There were
also functional and structural changes in the myocardium,
changes in electrocardiographic activity, such as increased P
wave dispersion, and structural changes in coronary vessels
in psoriatic patients (Figure 4)[ 7, 19, 144].
8. NTproBNP
In recent years, the probable usefulness of NTproBNP as a
biomarker of heart failure (HF) has been established. There
was a positive correlation observed between NT-pro BNP in
blood serum of psoriatic patients and heart diseases as well
as acceptation of the disease [145].
9. Lipidand Immunologic Abnormalities
In psoriasis, the association between lipid and immuno-
logic abnormalities was observed, that is why the disease
could be described as an immunometabolic syndrome
[128, 146]. Psoriasis is a chronic inﬂammation character-
ized by increased Th-1 and Th-17 T cell activity [128].
The signiﬁcant role of cytokines, such as TNF-α,I L - 6 ,8 Mediators of Inﬂammation
IL-8, IFN-gamma, IL-1, and IL-17 in the generation of
proatheromatous abnormalities (dyslipidemia, insulin resis-
tance, endothelial dysfunction, clotting system activation,
and pro-oxidative stress) was reported [127, 128, 146,
147]. TNF-α is a potent activator of c-Jun amino-terminal
kinase,which stimulates the main regulator of proinﬂam-
matory activity protein-1 and is connected with obesity
[128]. TNF-α can also lead to insulin resistance by inhibiting
phosphorylation of insulin receptor tyrosine and of insulin
receptor substrate 1. Treatment with TNF-αinhibitorsaﬀects
theincreaseofHDLlevel[128];inparticular,TNFmayaﬀect
endothelium dysfunction by decreasing the levels of nitric
oxide synthase and cyclooxygenase 1 [127].
10. Effects of Antipsoriaticsand
Hypolipemic Drugs on Psoriasis
Antipsoriatic drugs can be also responsible for the lipid
proﬁle disturbances in psoriatic patients, because of their
actiononthecirculatinglipids[148–156].Retinoidshavethe
most potent activity on increasing the levels of triglycerides,
total cholesterol, LDL cholesterol, and VLDL cholesterol
and simultaneously decreasing the HDL fraction [137–140].
There are some reports that the diet enriched with ﬁsh oil
can reduce side eﬀects of these drugs [157, 158]. Cyclosporin
has milder eﬀects on the lipid proﬁle, but it can also lead to
some abnormalities for example TG elevation [159]. TNF-α
inhibitors can cause an increase of serum triglyceride levels,
but they have beneﬁcial eﬀects on the increase of HDL level
and are able to decrease blood insulin levels [141, 160–162].
Hyperlipidemia is treated with statins which eﬀectively
reduce CRP and TNF-α levels as well as decrease levels of
low-density lipoproteins and alleviate the arterial stiﬀness.
Statins also downregulate adhesion molecules such as LFA-
1 and ICAM-1 on leukocytes and endothelial cells which
are essential in leukocyte activation, leukocyte migration
to inﬂammatory sites, and immunologic cytotoxicity [163].
Statins have the inhibiting action on the expression of MHC
II molecules, chemokine receptors on Th-1 cell and the
production of NO [163] .T h e s ed ru gsa r eg e n e ra l l yb e n e ﬁ c i a l
for psoriatic patients and reduce the risk of cardiovascular
diseases. However, there was also a case of exacerbation
of psoriasis after the treatment with three diﬀerent statins
and bezaﬁbrate [164]. Fibrates, used to decrease cholesterol
levels,mayalsoaﬀectrapidandacutedevelopmentofclinical
symptoms of psoriasis.
11. Summary
The lipid disturbances are recognised as a very important
partinthepathogenesisofpsoriasis.Theresultsofthemajor-
ity of the studies are coherent and indicate that the increased
total cholesterol, LDL cholesterol and/or triglycerides, and
decreased HDL cholesterol in psoriatic patients’ serum the
compositionofapolipoproteins,andincreasedproductionof
oxygen metabolites are features of the metabolic syndrome.
Thesefactorshavealsoagreatimpactonsomecomorbidities
observed in psoriatic patients especially on cardiovascular
diseases. These lipid disturbances are also connected with
immunological abnormalities, that is why psoriasis could
be classiﬁed as an immunometabolic disease. In spite of
the intensive investigations, the explanation of the steps of
disease mechanisms in psoriasis have not been recognised
so far. On the basis the literature data, further studies
should be designed to connect the lipid and immunological
disturbances.
The review of the last years suggests an introduction
of some new therapeutic methods for psoriatic patients
as for example statins. Their immunomodulatory activities
like inﬂuence on T cells and antigen presenting cells func-
tion, inﬂuence on leukocyte adhesion and endothelial cell
function are discussed. In many papers the importance of
reduction of animal fat, introduction of ﬁsh and plant oil,
preparations with the omega-6 and omega-3 fatty acids as
well as BMI reduction, prevention of obesity and quitting
addictions were suggested.
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